Cargando…

The IL-1 inhibitor Canakinumab for Familial Mediterranean Fever: the Greek experience in 12 patients

Detalles Bibliográficos
Autores principales:	Laskari, K, Boura, P, Dalekos, GN, Garyfallos, A, Karokis, D, Pikazis, D, Settas, L, Skarantavos, G, Tsitsami, E, Sfikakis, PP
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600059/ http://dx.doi.org/10.1186/1546-0096-13-S1-P72

Ejemplares similares

Indications and efficacy of canakinumab in Familial Mediterranean Fever: report of three cases
por: Tsinti, Maria, et al.
Publicado: (2014)

Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015)

Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis
por: Kosmidis, Michalis L., et al.
Publicado: (2019)

The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever
por: Sozeri, Betul, et al.
Publicado: (2016)

Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever
por: Sener, Seher, et al.
Publicado: (2023)

Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment
por: Alpa, Mirella, et al.
Publicado: (2015)

Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine
por: Berdeli, Afig, et al.
Publicado: (2019)

Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases
por: Yücel, Burcu Bozkaya, et al.
Publicado: (2021)

A Case of Hyperimmunoglobulinemia D Syndrome Successfully Treated with Canakinumab
por: Tsitsami, Elena, et al.
Publicado: (2013)

Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever
por: Gül, Ahmet, et al.
Publicado: (2015)

Canakinumab: can it untie the Gordian knot of cardiovascular disease in patients with familial Mediterranean fever?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever
por: Karabulut, Yusuf, et al.
Publicado: (2022)

Improvement of Liver Involvement in Familial Mediterranean Fever After the Introduction of Canakinumab: A Case Report
por: Massaro, Maria Grazia, et al.
Publicado: (2020)

The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
por: Kacar, Mark, et al.
Publicado: (2020)

Effectiveness of Colchicine or Canakinumab in Japanese Patients with Familial Mediterranean Fever: A Single-Center Study
por: Yoshida, Shuhei, et al.
Publicado: (2023)

Safe and effective canakinumab-treatment of neonatal onset multisystem inflammatory disease (NOMID)/ chronic infantile neurologic cutaneous and articular (CINCA)
por: Tsinti, M, et al.
Publicado: (2015)

Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience
por: Kavrul Kayaalp, Gülşah, et al.
Publicado: (2023)

Development of focal segmental glomerulosclerosis in a patient with Familial Mediterranean Fever resistant to colchicine therapy under treatment with Canakinumab
por: Barut, K, et al.
Publicado: (2015)

Combination of vial culture and broad-range PCR for the diagnosis of spontaneous bacterial peritonitis: experience in a Greek tertiary care hospital
por: Malli, E., et al.
Publicado: (2018)

Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial
por: Ozen, Seza, et al.
Publicado: (2020)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

The portrait of Familial Mediterranean Fever in N. Greek pediatric patients: a 30-year experience
por: Pratsidou-Gertsi, P, et al.
Publicado: (2015)

In vivo study of pro-inflammatory cytokine changes in serum and synovial fluid during treatment with celecoxib and etoricoxib and correlation with VAS pain change and synovial membrane penetration index in patients with inflammatory arthritis
por: Theodoridou, Athina, et al.
Publicado: (2017)

Long-term impact of juvenile idiopathic arthritis in the Greek adults' psychosocial life
por: Dimopoulou, Despoina, et al.
Publicado: (2014)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

Case report on the use of canakinumab for treatment of recurrent fevers and proteinuria in refractory systemic lupus erythematosus
por: Yavari, Kimia, et al.
Publicado: (2023)

The coming of the Greeks to Provence and Corsica: Y-chromosome models of archaic Greek colonization of the western Mediterranean
por: King, Roy J, et al.
Publicado: (2011)

OR10-006 - Canakinumab in patients with TRAPS
por: Lachmann, HJ, et al.
Publicado: (2013)

Canakinumab and Lung Cancer: Intriguing, but Is It Real?
por: Chabner, Bruce A., et al.
Publicado: (2018)

Treatment of refractory Yao syndrome with canakinumab
por: Brailsford, Caroline J., et al.
Publicado: (2022)

An experience of use of canakinumab IL-1 inhibitor in children with cryopyrin-associated periodic syndromes (CAPS)
por: Salugina, Svetlana O, et al.
Publicado: (2014)

Conformity to traditional Mediterranean diet and cancer incidence: the Greek EPIC cohort
por: Benetou, V, et al.
Publicado: (2008)

Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics
por: Ait-Oudhia, S, et al.
Publicado: (2012)

Dry Eye Signs and Symptoms Persist During Systemic Neutralization of IL-1β by Canakinumab or IL-17A by Secukinumab
por: Grosskreutz, Cynthia L., et al.
Publicado: (2015)

Could the Majority of the Greek and Cypriot Population Be Vitamin D Deficient?
por: Xyda, Souzana E., et al.
Publicado: (2022)

IL1-blocking therapy in colchicine-resistant familial Mediterranean fever
por: Köhler, Birgit Maria, et al.
Publicado: (2018)

Maintenance of efficacy of canakinumab in SJIA at the individual patient level in a 12-week pooled dataset
por: Ravelli, A, et al.
Publicado: (2014)

Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry
por: Vitale, Antonio, et al.
Publicado: (2022)

PW01-012 – Canakinumab in patients with FMF
por: Ugurlu, S, et al.
Publicado: (2013)

Canakinumab for the treatment of different refractory autoinflammatory disorders
por: Grein, Ingrid HR, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_nfgpoo8ccef4lukf6i44muord9